We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation.
- Authors
Lin, Shin-Yi; Kuo, Ching-Hua; Ho, Li-Ting; Liu, Yen-Bin; Huang, Chih-Fen; Tang, Sung-Chun; Jeng, Jiann-Shing
- Abstract
Background and Purpose: Edoxaban exposure varies across different ethnicities. The purpose of our study was to examine the risk factors associated with high or low edoxaban concentrations in Asian populations. Methods: Participants with atrial fibrillation who were undergoing edoxaban therapy were enrolled. Peak (1–4 h after edoxaban administration) and trough (24 ± 4 h from the last edoxaban dose) blood samples were collected to measure edoxaban concentrations using ultrahigh-performance liquid chromatography with tandem mass spectrometry. The edoxaban concentrations were compared to those observed in clinical trials to define a higher- or lower-than-expected range. Multivariate logistic regression was used to analyze the risk factors associated with high or low edoxaban concentrations. Results: Eighty participants (49 men, 61.3%) were enrolled and provided 78 trough and 76 peak samples. Twenty participants (25.6%) were determined to have low trough concentrations, which was associated with higher creatinine clearance and the use of the 30 mg regimen (odds ratio [OR] and 95% confidence interval [CI], 1.06 [1.01, 1.11], p = 0.01 and 5.77 [1.34, 24.75], p = 0.02, respectively). In contrast, 21 participants (27.6%) had high peak concentrations, which was associated with an off-label overdosing regimen (OR = 4.68 [1.23, 17.70], p = 0.02). Conclusion: Our study identified factors associated with increased or decreased edoxaban exposure. The measurement of edoxaban concentration may be recommended for patients with selected characteristics.
- Subjects
TANDEM mass spectrometry; LIQUID chromatography-mass spectrometry; ATRIAL fibrillation; ATRIAL arrhythmias; EDOXABAN
- Publication
Frontiers in Pharmacology, 2021, Vol 12, p1
- ISSN
1663-9812
- Publication type
Article
- DOI
10.3389/fphar.2021.736826